Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03090100 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,048
- Enrollment target
NCT03090100 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 1,048 participants.
The verdict
NCT03090100, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,048 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
Interventions
- DRUG Placebo
- DRUG Guselkumab
- DRUG Secukinumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,048 participants |
| Start Date | 2017-04-27 |
| Est. Completion | 2018-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03090100
The ClinicalTrials.gov registry entry for NCT03090100 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,048 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03090100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03090100 about?
NCT03090100 is a clinical study titled "A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis". The purpose of this study is to evaluate the efficacy of guselkumab compared with secukinumab for the treatment of participants with moderate to severe plaque-type psoriasis.
What is the current status of trial NCT03090100?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,048 participants. The study started on 2017-04-27. Estimated completion is 2018-09-20.
What interventions are being tested in trial NCT03090100?
The interventions under investigation include: Placebo (DRUG), Guselkumab (DRUG), Secukinumab (DRUG).
Who is sponsoring clinical trial NCT03090100?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.